<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681132</url>
  </required_header>
  <id_info>
    <org_study_id>2018/988</org_study_id>
    <nct_id>NCT03681132</nct_id>
  </id_info>
  <brief_title>The Norwegian Nucleoside Analogue Stop Study</brief_title>
  <acronym>Nuc-Stop</acronym>
  <official_title>The Norwegian Nucleoside Analogue Stop Study: a Randomized Open-label Trial in HBeAg Negative Chronic Hepatitis B, Aiming at Achieving a Functional Cure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akershus University Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Addis Ababa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Paul's Hospital Millennium Medical College, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bærum Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Drammen Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tønsberg Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stavanger University Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ålesund Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bodø Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Globally, an estimated 257 million individuals have chronic hepatitis B-virus infection
      (CHB). In the absence of treatment 15-40% of these will progress to liver cirrhosis and/or
      hepatocellular carcinoma. Oral antiviral treatment suppresses the virus and improves
      prognosis, but less than 0.5% per year achieve a &quot;functional cure&quot; (i.e. HBsAg loss). One
      remaining controversy, therefore, is whether antiviral treatment must continue life-long.
      Observational studies have assessed stopping antiviral treatment after years of viral
      suppression; however, HBsAg loss has rarely been seen. But interestingly, a few small trials
      that chose watchful waiting instead of re-initiation of treatment when reactivation occurred,
      achieved 40% HBsAg loss during 6 years follow-up.

      The present proposal is a randomized controlled trial that will assess the safety, efficacy,
      and cost-effectiveness of treatment discontinuation - and delayed restart - in HBeAg negative
      CHB. The study is sufficiently powered to address the hypotheses, and a pilot study that
      demonstrates feasibility has been performed. Patients will be enrolled at 12 Norwegian
      hospitals, in addition to our collaborating institution in Ethiopia - the largest CHB
      treatment center in sub-Saharan Africa. If the study shows that discontinuation is safe and
      effective, it will directly impact both national and international treatment guidelines.

      Main objective:

      -To study whether stopping nucleoside analogue (NA) therapy - and delaying re-start - can
      trigger an immune response and set off a functional cure (viz HBsAg loss)

      Secondary objectives:

        -  Assess whether stopping NA therapy - and delaying re-start - leads to a higher chance of
           HBsAg loss

        -  Assess the safety of stopping NA therapy - and delaying re-start - in terms of hepatic
           decompensation, fibrosis progression, and/or adverse events

        -  Study whether stopping NA therapy - and delaying re-start - leads to a higher chance of
           sustained off-therapy immune control (low viral load and normal ALT)

        -  Assess the quality of life and cost-effectiveness of stopping NA therapy - and delaying
           re-start

        -  Identify predictors of HBsAg loss
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg loss</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Undetectable HBsAg measured by a standard assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to HBsAg loss</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Time from randomization to undetectable HBsAg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to re-start of antiviral therapy</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Time from randomization to re-start of therapy according to the specified criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe unintended medical events</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Liver failure or other liver-related grade 4/5 SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune control</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Sustained off-therapy response viz HBV DNA &lt;2000 IU/ml and ALT &lt;40 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in health-related quality of life</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Changes in the EuroQol standardized measure of health status (EQ-5D-5L) score. The summary index (from 0 to 1) as described by the manufacturer (euroqol.org) will be employed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis evolution</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Changes in transient elastography from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Low-threshold re-start</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Re-start antiviral therapy if HBV DNA viral load &gt;2000 IU/ml and ALT &gt;80 U/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-threshold re-start</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Re-start antiviral therapy if:
ALT &gt;100 U/L persisting for more than 4 months without any spontaneous decline toward normal; OR
ALT &gt;400 U/L persisting for more than 2 months in consecutive assays.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stop of therapy</intervention_name>
    <description>The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.</description>
    <arm_group_label>High-threshold re-start</arm_group_label>
    <arm_group_label>Low-threshold re-start</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18-70 years) with HBeAg negative chronic hepatitis B

          -  HBeAg negative at start of antiviral therapy

          -  Treated minimum 2 years with either tenofovir or entecavir without interruption (i.e.
             no self-reported episodes of ≥2 weeks off therapy)

          -  Full viral suppression &gt;2 years: at least 3 measurements at least 6 months apart with
             at least 24 months between the first and last measurement.

          -  Most recent liver fibrosis assessment, performed within the past 12 months, does not
             show advanced fibrosis (i.e. Metavir score &lt;F3 or Fibroscan &lt;9 kPa). For the (few)
             patients who lack pre-treatment fibrosis assessment, a more conservative Fibroscan
             threshold of &lt;8 kPa will apply.

        Exclusion Criteria:

          -  A history of decompensated liver disease, either by clinical signs (ascites,
             encephalopathy, portal hypertension, jaundice) or suggestive laboratory results (total
             bilirubin &gt;38 umol/L, INR &gt;1.5, platelets &lt;75,000/mm3, serum albumin &lt;30 g/L).

          -  Any previous diagnosis of cirrhosis, either by liver biopsy (Metavir score F4) or
             elastography (Fibroscan &gt;12 kPa). Elastography results with concomitant ALT &gt;200 U/L
             are not considered.

          -  Previous hepatocellular carcinoma (HCC).

          -  Co-infections with HIV, hepatitis C or hepatitis D.

          -  Other disease or medication that can interfere with the study (e.g. ongoing alcohol or
             illicit drug abuse, immunosuppressive medication, other active liver disease, or any
             other condition which in the opinion of the physician is incompatible with
             participation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>København</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Paul Hospital Millennium Medical College</name>
      <address>
        <city>Addis Abeba</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bodø Hospital</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bærum Hospital</name>
      <address>
        <city>Sandvika</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tønsberg Hospital</name>
      <address>
        <city>Tønsberg</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karonlinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Ethiopia</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Asgeir Johannessen</investigator_full_name>
    <investigator_title>Consultant/ researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

